By Yifan Wang
Shares of Cansino Biologics rose in Hong Kong, as the regulatory approval for the Chinese biotech firm’s vaccine gave investors a boost of confidence.
The stock has gained as much as 8.2% and was last up by 4.8% at HK$26.35.
The rally came after Cansino Biologics said late Sunday that its recombinant zoster vaccine, codeveloped with the Nasdaq-listed Vaccitech, received a regulatory green light to start clinical trials in Canada.
Canadian health authorities issued a “no objection” letter for clinical trials for the vaccine, the company said. Both the intramuscular injection version and the aerosol inhalation version of the vaccine are approved for clinical trials, it added.
Write to Yifan Wang at [email protected]
Read the full article here
